We are live on ! Find out more
KROS icon

Keros Therapeutics
KROS

Fund managers haven’t disclosed any holdings of KROS yet.

KROS Hedge Fund Activity: Q1 2026 in Review

151 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Keros Therapeutics (KROS) for Q1 2026, worth a combined $206M — down 50% from $409M a quarter earlier.

Sellers outnumbered buyers: 40 funds closed out of KROS and 27 opened new positions — a net loss of 13 holders — while 55 trimmed existing stakes and 48 added.

The largest buyer was Nantahala Capital Management, adding an estimated $15.4M. The largest seller was Arrowstreet Capital, cutting an estimated $11.5M.

  • 151 institutional investors held Keros Therapeutics (KROS) as of Q1 2026, down from 166 in Q4 2025.
  • Funds reported $206M of Keros Therapeutics stock for Q1 2026, down 50% quarter-over-quarter.
  • 27 funds opened new Keros Therapeutics positions in Q1 2026 and 40 closed out, a net change of -13 holders.
  • The largest Keros Therapeutics buyer in Q1 2026 was Nantahala Capital Management, an estimated $15.4M added.
  • The largest Keros Therapeutics seller in Q1 2026 was Arrowstreet Capital, an estimated $11.5M sold.

Based on aggregated 13F filings for Q1 2026.